Fox Chase Cancer Center

Oncology & Cancer

New therapy on the horizon for ALK+ non-small cell lung cancer

A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to ...

Oncology & Cancer

More cutting-edge cancer research supported by industry

Nearly half of the research presented at ASCO's annual meeting last year came from researchers with ties to companies, and the amount appears to be increasing every year, according to new findings from Fox Chase Cancer Center. ...

Oncology & Cancer

Scientists discover link between estrogen and tobacco smoke

The hormone estrogen may help promote lung cancer— including compounding the effects of tobacco smoke on the disease—pointing towards potential new therapies that target the hormone metabolism, according to new ...

Oncology & Cancer

New compound targets key mechanism behind lymphoma

Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on ...

Oncology & Cancer

New boost for pancreatic cancer therapy

Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar)—the chemotherapy drug that is considered standard therapy for the disease. Although ...

page 6 from 16